Technical Analysis for HURA - TuHURA Biosciences, Inc.

Grade Last Price % Change Price Change
F 3.42 3.95% 0.13
HURA closed up 8.94 percent on Wednesday, November 20, 2024, on 75 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 3.95%
Inside Day Range Contraction 3.95%
Wide Bands Range Expansion 3.95%
Below Lower BB Weakness 3.95%
Lower Bollinger Band Touch Weakness 3.95%
Oversold Stochastic Weakness 3.95%
Wide Bands Range Expansion 13.25%
Below Lower BB Weakness 13.25%
Down 3 Days in a Row Weakness 13.25%
Down 4 Days in a Row Weakness 13.25%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 3 hours ago
Down 5% about 3 hours ago
Down 3% about 3 hours ago
Down 2 % about 3 hours ago
Down 1% about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TuHURA Biosciences, Inc. Description

TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced Merkel Cell Carcinoma. In addition, TuHURA is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immune System Immunotherapy Tumor Cancer Immunotherapy Antineoplastic Drugs Checkpoint Inhibitor Tumor Microenvironment Pembrolizumab Adjunctive Therapy

Is HURA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.3635
52 Week Low 2.835
Average Volume 111,894
200-Day Moving Average 6.02
50-Day Moving Average 5.80
20-Day Moving Average 4.88
10-Day Moving Average 4.45
Average True Range 0.66
RSI (14) 26.47
ADX 42.45
+DI 7.99
-DI 38.57
Chandelier Exit (Long, 3 ATRs) 4.22
Chandelier Exit (Short, 3 ATRs) 4.90
Upper Bollinger Bands 6.46
Lower Bollinger Band 3.29
Percent B (%b) 0.0
BandWidth 64.97
MACD Line -0.64
MACD Signal Line -0.46
MACD Histogram -0.1852
Fundamentals Value
Market Cap 11.15 Million
Num Shares 3.39 Million
EPS -7.71
Price-to-Earnings (P/E) Ratio -0.43
Price-to-Sales 0.00
Price-to-Book 7.81
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.91
Resistance 3 (R3) 3.86 3.61 3.80
Resistance 2 (R2) 3.61 3.45 3.63 3.77
Resistance 1 (R1) 3.45 3.36 3.53 3.50 3.73
Pivot Point 3.20 3.20 3.24 3.22 3.20
Support 1 (S1) 3.04 3.04 3.12 3.09 2.85
Support 2 (S2) 2.79 2.95 2.81 2.81
Support 3 (S3) 2.63 2.79 2.78
Support 4 (S4) 2.68